Mechanisms of Mitochondrial Defects in Gulf War Syndrome
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2011 by Medical Neurogenetics, LLC.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Medical Neurogenetics, LLC
Collaborator:
Information provided by (Responsible Party):
John M. Shoffner, Medical Neurogenetics, LLC
ClinicalTrials.gov Identifier:
NCT01264471
First received: December 17, 2010
Last updated: September 20, 2011
Last verified: September 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to investigate possible causes for Gulf War Syndrome. Gulf War Syndrome is associated with increased incidences of amyotrophic lateral sclerosis (Lou Gehrig's Disease), pain syndromes, muscle complaints that include fatigue and myalgias (muscle pain), as well as other neurological symptoms. Abnormalities in the part of the cell known as mitochondria have been delineated in Gulf War Syndrome. Mitochondria are the "power plants" of the body. Mitochondria take the food you eat and break the food down into a form of energy that the body can use. The investigators propose that Gulf War Syndrome is determined by a complex interaction of factors that interfere with mitochondrial function. This study will be the first investigation of mitochondrial function in Gulf War Syndrome. The investigators objective is to establish the cause for symptoms in affected veterans, develop testing that can more easily identify Gulf War Syndrome, and ultimately develop treatment protocols for Gulf War Syndrome.
| Condition | Intervention |
|---|---|
|
Gulf War Syndrome Mitochondrial Disease |
Procedure: Skin biopsy Procedure: Blood Collection |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Cross-Sectional |
| Official Title: | Mechanisms of Mitochondrial Defects in Gulf War Syndrome |
Resource links provided by NLM:
Genetics Home Reference related topics:
ataxia neuropathy spectrum
childhood myocerebrohepatopathy spectrum
deoxyguanosine kinase deficiency
mitochondrial neurogastrointestinal encephalopathy disease
myoclonic epilepsy myopathy sensory ataxia
U.S. FDA Resources
Further study details as provided by Medical Neurogenetics, LLC:
Primary Outcome Measures:
- Characterize mitochondrial cellular energetics in Gulf War Syndrome patients [ Time Frame: approximately 2 years; once all data has been collected from study participants ] [ Designated as safety issue: No ]After collecting a skin and blood sample, mitochondrial cellular energetics in Gulf War Syndrome patients will be characterized by: 1. high resolution respirometry of intact cells, 2. quantitative analysis of individual mitochondrial proteins, 3. analysis of intact OXPHOS enzyme complexes and supercomplexes, 4. in gel enzyme activity assessment of intact OXPHOS enzyme complexes and supercomplexes, 5. mitochondrial DNA (mtDNA) copy number quantitation to assess for defects in regulation mtDNA replication and 6. cellular coenzyme Q10 quantitation.
Secondary Outcome Measures:
- Mitochondrial DNA [ Time Frame: approximately 2 years; once all data has been collected from study participants. ] [ Designated as safety issue: No ]Assess the mitochondrial DNA (mtDNA) from each patient with Gulf War Syndrome for mtDNA mutations by whole genome sequencing of leukocyte and skin cell mtDNA.
Biospecimen Retention: Samples With DNA
whole blood and tissue
| Estimated Enrollment: | 50 |
| Study Start Date: | May 2009 |
| Estimated Study Completion Date: | August 2012 |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Gulf War Syndrome patients
Gulf War veterans who have been diagnosed with Gulf War Syndrome.
|
Procedure: Skin biopsy
A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)
Other Name: skin sample
Procedure: Blood Collection
Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.
Other Names:
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Gulf War Veterans who have been diagnosed with Gulf War Syndrome
Criteria
Inclusion Criteria:
- Short-term memory loss or a severe inability to concentrate that affects work, school or other normal activities
- Muscle Pain, myalgias
- Pain without redness or swelling in a number of joints
- Intense or changing patterns of headaches
- Unrefreshing sleep
- After any exertion, weariness that lasts for more than a day
Exclusion Criteria:
- Organ failure (e.g. emphysema, cirrhosis, cardiac failure, chronic renal failure)
- Chronic infections (e.g. HIV/AIDS, hepatitis B or C)
- Rheumatic and chronic inflammatory diseases (e.g. systemic lupus erythematosis, Sjogren's syndrome, rheumatoid arthritis, inflammatory bowel disease, chronic pancreatitis.)
- Major neurologic diseases (e.g. multiple sclerosis, neuromuscular diseases, epilepsy or other disease requiring ongoing medication that could cause fatigue, stroke, head injury with residual neurologic deficits)
- Diseases requiring systemic treatment (e.g. organ or bone marrow transplantation; systemic chemotherapy; radiation of brain, thorax, abdomen, or pelvis)
- Major endocrine diseases (e.g. hypopituitarism, adrenal insufficiency)
- Myocardial infarction, heart failure
- Morbid obesity (body mass index >40)
- Permanent psychiatric exclusions: Lifetime diagnoses of bipolar affective disorders, schizophrenia or any subtype, delusional disorders of any subtype, dementias of any subtype, organic brain disorders, and alcohol or substance abuse within 2 years before onset of the fatiguing illness.
- History of allergic reaction to lidocaine
- History of keloid formation with skin incisions.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01264471
Please refer to this study by its ClinicalTrials.gov identifier: NCT01264471
Contacts
| Contact: Julie Decker | 404-769-5163 | jdecker@mnglab.com | |
| Contact: Maureen E Starnes, CPNP | 678-225-0222 | mstarnes@mnglab.com |
Locations
| United States, Georgia | |
| Medical Neurogenetics, LLC | Recruiting |
| Atlanta, Georgia, United States, 30342 | |
| Contact: Julie Decker 404-769-5163 jdecker@mnglab.com | |
| Principal Investigator: John M Shoffner, MD | |
Sponsors and Collaborators
Medical Neurogenetics, LLC
Investigators
| Principal Investigator: | John M Shoffner, MD | Medical Neurogenetics |
More Information
No publications provided
| Responsible Party: | John M. Shoffner, Medical Director, Medical Neurogenetics, LLC |
| ClinicalTrials.gov Identifier: | NCT01264471 History of Changes |
| Other Study ID Numbers: | H09378, GW080138 |
| Study First Received: | December 17, 2010 |
| Last Updated: | September 20, 2011 |
| Health Authority: | United States: Federal Government |
Keywords provided by Medical Neurogenetics, LLC:
|
Gulf War Syndrome Gulf War Illness Mitochondrial defects Mitochondrial disorders Persian Gulf Syndrome |
Additional relevant MeSH terms:
|
Mitochondrial Diseases Persian Gulf Syndrome Syndrome Disease |
Metabolic Diseases Occupational Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on February 27, 2015